Suicidality risk of cancer caregivers: a systematic review and meta-analysis of observational studies.

Ann MedFeb 2, 2026 (epub)
Clinical ResearchOncology (Medical)PsychiatryOpen access

Xia-Yin Zhu, Lu-Yi Hu, Min-Ya Jin et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis of observational studies examined suicidality risk among cancer caregivers. Seven studies included 638,188 exposed subjects and 4,203,957 nonexposed subjects. Pooled estimates showed higher suicidality among caregivers: the odds ratio was 1.91 (95% CI: 1.46-2.49) across studies reporting ORs, and the adjusted hazard ratio was 1.32 (95% CI: 1.16-1.50) across three cohort studies. Risk was also elevated for caregivers of patients with highly aggressive cancers and during the first 7 years after diagnosis.

Key findings

  • Across three cohort studies, caregivers had higher suicidality risk than nonexposed subjects (aHR = 1.32; 95% CI: 1.16-1.50).
  • The pooled OR from studies reporting odds ratios was 1.91 (95% CI: 1.46-2.49).
  • Caregivers of patients with highly aggressive cancers had greater risk (aHR = 1.66; 95% CI: 1.48-1.86).
  • Risk remained elevated within the first 7 years after a patient's cancer diagnosis (aHR = 1.42; 95% CI: 1.04-1.94).

Why it matters

The findings indicate that suicidality may be an important concern beyond the patient, affecting people providing cancer care as well. The elevated estimates, including among caregivers of patients with highly aggressive cancers, support awareness of caregiver mental health as part of the broader response to cancer-related burden. Because the evidence is observational, the results identify risk patterns rather than proving that caregiving causes suicidality.

What to keep in mind

The evidence comes from only seven observational studies, with differing designs and effect measures; these findings cannot establish causation.

Source

Published in Ann Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.